AN2 Therapeutics, Inc. — SEC Form D Filing
AN2 Therapeutics, Inc. filed an SEC Form D on March 25, 2026, reporting $40.00M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- March 25, 2026
- Amount reported
- $40.00M
- Industry
- Pharmaceuticals
- Website
- https://www.an2therapeutics.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
AN2 Therapeutics addresses the need for new therapeutic options in treating infectious diseases and oncology.
Solution
They utilize their boron chemistry platform to develop novel boron-based compounds that aim to be best in class therapeutics.
Verdict
Investors backed AN2 Therapeutics because the promise of new therapeutic options for infectious diseases and oncology is a persistent need, not because the market was saturated with effective alternatives. Implicitly, they were betting on the uniqueness of boron chemistry in addressing these medical challenges, while acknowledging limited upside in terms of widespread adoption and competition from established therapies.
Source: SEC EDGAR Form D filing